Synthesis, characterization and evaluation of [¹⁶⁹Yb]Yb-labeled tailored hydroxyapatite nanospheres for potential application in nanobrachytherapy.

Authors

Sourav Patra, Khajan Singh, Partha Sarathi Ghosh, K V Vimalnath, Priya Banerjee, Ravi Kumar, Chandan Kumar, Avik Chakraborty, Santosh Gupta, D Bhattacharyya, Rubel Chakravarty, Sudipta Chakraborty

Published in

Nuclear medicine and biology. Volume 160-161. Pages 109663. Aug 05, 2026. Epub Aug 05, 2026.

Abstract

The introduction of radiolabeled nanoparticles in the realm of brachytherapy has led to a promising therapeutic strategy for cancer management called 'nanobrachytherapy'. In the quest of developing a potent radiolabeled inorganic biomaterial for use in nanobrachytherapy, we report the synthesis and evaluation of ¹⁶⁹Yb [T_1/2 = 32.02 d]-labeled glucuronic acid (GA) functionalised hydroxyapatite (HA) nanoparticles (GAHAnp) and established its potency in pre-clinical settings.
GAHAnp having average hydrodynamic diameter of 45 ± 3 nm was synthesized and characterized using various analytical methods. Ytterbium-169 was produced with adequate radionuclidic purity by direct neutron activation of isotopically enriched Yb-target in research reactor. Radiolabeling protocol of GAHAnp with ¹⁶⁹Yb to obtain [¹⁶⁹Yb]Yb-GAHAnp in high yield and purity was optimized. Adsorption of [¹⁶⁹Yb]Yb³⁺ on GAHAnp followed Langmuir-Freundlich isotherm and pseudo-second order kinetics. The mechanism of incorporation of [¹⁶⁹Yb]Yb⁺³ on GAHAnp was investigated using density functional theory (DFT) and experimentally verified by radiotracer investigations and XAFS studies, which suggested replacement of Ca²⁺ with Yb³⁺ in GAHAnp matrix. The [¹⁶⁹Yb]Yb-GAHAnp formulation demonstrated excellent in vitro radiochemical stability in physiological media and cell toxicity in Raji cells. SPECT/CT imaging and ex vivo biodistribution carried out after intra-tumoral administration of [¹⁶⁹Yb]Yb-GAHAnp in tumor bearing mice showed near-complete retention of the formulation in the tumor mass upto 2 weeks. Tumor growth could be significantly arrested after administration of 30 MBq dose of the formulation compared to the control.
These findings demonstrate the potential utility of synthesized [¹⁶⁹Yb]Yb-GAHAnp formulation in the treatment of solid tumors through nanobrachytherapy.

PMID:
42574780
Bibliographic data and abstract were imported from PubMed on 11 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.